A COA for standardized ginkgo biloba extract will show two numbers: 24% flavonol glycosides and 6% terpene lactones. Most buyers check the first and assume the second. That assumption is where premium formulas and commodity extracts quietly diverge. The 6% terpene lactone figure is a total — it covers ginkgolides A, B, C, J, and bilobalide combined — but these are not equivalent compounds. Ginkgolide B is the most extensively studied of the group, with the strongest documented PAF-inhibitory activity, and it is the one most likely to be missing from a breakdown that a supplier was not asked to provide. This article explains what ginkgolide B is, how it differs from the other terpene lactones, and what to require on a COA when the terpene lactone fraction actually matters to the specification.
What Are Terpene Lactones in Ginkgo Biloba?
Terpene lactones are one of two major compound classes in standardized ginkgo extract — the other being flavonol glycosides. They are structurally unique to Ginkgo biloba; no other commercially significant plant produces them in meaningful quantities, which is part of what makes ginkgo extract chemically distinctive rather than interchangeable with other botanical antioxidants.
The terpene lactone fraction divides into two subgroups. Ginkgolides — A, B, C, J, and M — are diterpene trilactones with a cage-like carbon skeleton that took decades to fully characterize; their total synthesis was first achieved in 1988, a landmark in natural products chemistry given the structural complexity involved.[1][5] Bilobalide is a sesquiterpene trilactone — smaller and structurally distinct from the ginkgolides, though grouped with them in the terpene lactone fraction of a COA. In the Ph. Eur. specification for EGb 761-type extracts, the 6% terpene lactone target breaks down to approximately 2.8–3.4% ginkgolides A, B, and C combined, plus 2.6–3.2% bilobalide.[2]
| Compound | Type | Typical % in 24/6 Extract | Primary Research Focus |
|---|---|---|---|
| Ginkgolide A | Diterpene trilactone | ~1.0–1.4% | PAF inhibition (moderate potency) |
| Ginkgolide B | Diterpene trilactone | ~0.8–1.2% | PAF inhibition (highest potency among ginkgolides) |
| Ginkgolide C | Diterpene trilactone | ~0.8–1.2% | PAF inhibition (moderate potency) |
| Ginkgolide J | Diterpene trilactone | Trace | Weak PAF activity |
| Bilobalide | Sesquiterpene trilactone | ~2.6–3.2% | Neuroprotective activity; distinct from ginkgolides |
Why Ginkgolide B Is the Most-Studied Terpene Lactone
Among the ginkgolides, the research on PAF inhibition consistently points to ginkgolide B as the most potent. In a pharmacokinetic study that directly compared PAF-inhibitory activity across ginkgolides A, B, C, and J at equal concentrations, ginkgolide B exhibited the strongest inhibition of PAF-induced platelet aggregation, followed by ginkgolides A and C, with ginkgolide J showing only weak activity.[3] Bilobalide showed negligible platelet-inhibitory activity in the same study.
Platelet-activating factor is a phospholipid mediator involved in platelet aggregation and inflammatory signalling. The research interest in ginkgolide B’s PAF antagonism stems from its potential relevance to microcirculation — the area that connects ginkgo research to circulatory applications.[4] This is why formulators building premium cognitive or circulation-category products want ginkgolide B specified separately, not folded into a total terpene lactone percentage: it is not interchangeable with the other ginkgolides, and a COA showing 6% total terpene lactones says nothing about how much of that is ginkgolide B versus the less-studied ginkgolide J or bilobalide.
What “6% Terpene Lactones” on a COA Does and Does Not Tell You
The 6% figure on a COA confirms that the total of ginkgolides plus bilobalide meets the Ph. Eur. minimum. It does not confirm the individual breakdown. Two extracts can both show 6.2% total terpene lactones while having very different ginkgolide B contents — one might contain 1.1% ginkgolide B and the other 0.6%, depending on the source leaf and processing. From a specification standpoint, 6% total is a floor, not a guarantee of composition within that fraction.
The Ph. Eur. monograph is more specific than a typical COA: it sets sub-ranges for ginkgolides A, B, C combined (2.8–3.4%) and bilobalide separately (2.6–3.2%), measured by HPLC.[2] A supplier producing to Ph. Eur. should be able to provide these sub-figures per batch on request. If a supplier can only provide the 6% total and not the individual breakdown, that is a signal about their analytical capability — and about whether their process is genuinely controlled to Ph. Eur. standards or just passing the headline number.
• Total terpene lactones: ≥6% by HPLC
• Ginkgolides A + B + C combined: 2.8–3.4% (Ph. Eur. range)
• Bilobalide: 2.6–3.2% (Ph. Eur. range)
• Ginkgolide B specifically: confirmed per batch for premium applications
If a supplier cannot provide the individual breakdown per batch, the 6% total figure is unverified at the sub-fraction level.
How Ginkgolide B Relates to Ginkgolic Acid — a Common Confusion
One source of confusion in ginkgo specifications is the similarity in names between ginkgolide B and ginkgolic acid. They are unrelated compounds with opposite roles. Ginkgolide B is a beneficial terpene lactone you want to confirm is present at the right level; ginkgolic acid is a cytotoxic alkylphenol you want confirmed to be below 5 ppm.
Ginkgolic acids are found in the raw leaf and seed and must be removed during extraction. They are structurally similar to urushiol, the contact allergen in poison ivy, and show cytotoxicity in cell studies at higher concentrations. The Ph. Eur. and USP monographs both set a hard limit of <5 ppm. Commodity extracts that have not been properly processed for ginkgolic acid removal can exceed this limit while still hitting the 24% and 6% marker targets — which is why ginkgolic acid testing per batch is a non-negotiable third pillar of a complete COA, separate from either marker compound.
Specifying Ginkgolide B When Sourcing
For most supplement applications, a COA showing 24% flavonol glycosides, 6% terpene lactones, and ginkgolic acid <5 ppm per batch is sufficient — this is the documented EGb 761-type composition that the published research is built on. For the full context on what the EGb 761 reference standard means for sourcing, see our guide to EGb 761 and the ginkgo biloba reference standard.
For premium cognitive or circulation-category products where the terpene lactone breakdown is part of the formula’s positioning, the additional requirement is straightforward: request ginkgolide B confirmed separately per batch, alongside the ginkgolides A+B+C combined figure and bilobalide. Any manufacturer producing genuinely to Ph. Eur. standards runs this analysis as part of their standard HPLC method — it is not an exotic request, and a supplier who cannot provide it is not operating at that level of analytical control.
For the broader context of how flavonol glycosides and terpene lactones work together as the two-marker system behind the 24/6 standard, see our technical guide to ginkgo flavone glycosides and terpene lactones. For sourcing specifications and available grades, see the Valeherb ginkgo biloba extract product page.
Frequently Asked Questions
What is ginkgolide B and why does it matter in ginkgo extract?
Ginkgolide B is one of five ginkgolide compounds in the terpene lactone fraction of standardized ginkgo biloba extract. It is the most extensively studied for platelet-activating factor inhibition — research comparing ginkgolides A, B, C, and J at equal concentrations found ginkgolide B had the strongest PAF-inhibitory activity. This makes it the terpene lactone most relevant to circulatory applications and the one most often requested as a separate COA figure by formulators building premium cognitive or circulation-category products.
Is ginkgolide B the same as ginkgolic acid?
No — they are completely different compounds with opposite roles. Ginkgolide B is a beneficial diterpene trilactone in the terpene lactone fraction, present at roughly 0.8–1.2% in a Ph. Eur.-compliant extract, and is a key marker of quality. Ginkgolic acid is a cytotoxic alkylphenol found in raw ginkgo leaf that must be removed during extraction and is controlled to below 5 ppm in compliant material. The name similarity causes confusion, but they have nothing structurally or functionally in common.
Why does “6% terpene lactones” not fully describe the ginkgolide B content?
The 6% total covers ginkgolides A, B, C, J, and bilobalide combined — five distinct compounds with different activities. Bilobalide alone accounts for roughly half the total (2.6–3.2%), and ginkgolide J has weak PAF activity. Two extracts with the same total terpene lactone percentage can have very different ginkgolide B contents depending on source material and processing. For applications where ginkgolide B content matters, a per-batch COA breakdown — not just the total figure — is the only way to verify what is actually present.
How should I specify ginkgolide B on a purchase order?
Request the full terpene lactone breakdown on the COA: total terpene lactones ≥6% by HPLC, ginkgolides A+B+C combined in the 2.8–3.4% Ph. Eur. range, bilobalide in the 2.6–3.2% range, and ginkgolide B confirmed individually per batch. Any manufacturer operating to Ph. Eur. standards runs this analysis as part of their standard HPLC method. A supplier who cannot provide per-batch individual breakdown figures is not producing to that level of analytical control, regardless of what the product sheet states.
What is bilobalide and how does it differ from ginkgolides?
Bilobalide is a sesquiterpene trilactone — smaller and structurally distinct from the diterpene ginkgolides — that makes up roughly half of the total 6% terpene lactone fraction in a Ph. Eur.-compliant extract. Its research focus is on neuroprotective activity, distinct from the PAF-inhibitory mechanisms studied for the ginkgolides. Because bilobalide dominates the terpene lactone total numerically, a 6% total figure without a breakdown can obscure the actual ginkgolide content — which is why formulators who care specifically about PAF-related mechanisms ask for the ginkgolide sub-fraction separately.
References
[1] Corey EJ, Kang MC, Desai MC, Ghosh AK, Houpis IN. (1988). Total synthesis of (±)-ginkgolide B. Journal of the American Chemical Society, 110(2), 649–651. doi:10.1021/ja00210a083
[2] European Directorate for the Quality of Medicines & HealthCare. (2020). Ginkgo Dry Extract, Refined and Quantified. European Pharmacopoeia 10th Edition, Monograph 01/2016:1827. edqm.eu
[3] Yin Z, Meng F, Chen H, et al. (2018). Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. Drug Metabolism and Disposition, 47(1), 1–10. PMC6289403
[4] Pittler MH, Ernst E. (2000). Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. American Journal of Medicine, 108(4), 276–281. PMID: 11014719
[5] Kleijnen J, Knipschild P. (1992). Ginkgo biloba. Lancet, 340(8828), 1136–1139. doi:10.1016/0140-6736(92)93158-J
